Theralase Technologies Inc.: Theralase Releases Corrected an

In the Performance to Primary, Secondary and Tertiary Objectives second table the 90 day results were misstated and has been corrected in this press release.TORONTO, ON / ACCESSWIRE / May 30, 2023 / Theralase®

Related Keywords

Toronto , Ontario , Canada , Chicago , Illinois , United States , California , San Francisco , Russia , American , Canadian , Russian , Roger Dumoulin White , Arkady Mandel , Regulation Services Provider , Venture Exchange , American Urology Association , Clean Technology , Life Sciences , Company Annual Meeting On , Company Photo Dynamic Compounds , Ontario Securities Commission , International Bladder Cancer Group , Development Expenses , Toronto Stock Venture Exchange , Technologies Inc , Company Board Of Directors , Theralase Technologies Inc , Theralase Technologies Inc View , Toronto Stock Exchange Venture , American Society Of Clinical Oncology , Company Anti , Tertiary Objectives , Photo Dynamic Compounds , Financial Statements , Consolidated Statements , Canadian Dollars , Anti Cancer Therapy , Chief Executive Officer , Chief Scientific Officer , Settlement Agreement , Annual Meeting , Diversified Industries , Scientific Advisory Board , Indeterminate Response , Urothelial Cell Carcinoma , Complete Response , Clinical Oncology , Evaluable Patients , Principal Investigator , Study Treatment , American Society , Genito Urinary , Cancer Symposium , Prostate Cancer , Urology Association , Unresponsive Nonmuscle Invasive Bladder Cancer , Developing Drugs , Unresponsive Non Muscle Invasive Bladder Cancer , Carcinoma In Situ , Study Sites , Adverse Events , Study Drug , Study Device , More Information , Chief Financial , Gefallene Big Techs , Theralase , Technologies , Eleases , Uncorrected , Gestated , Dress , Release , Q2023 , Interim , Financial , Statements ,